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Summary NM23 is a putative metastasis-suppressor gene for some human cancers. Here we have studied
NM23 expression during melanoma progression using Northern blotting and immunocytochemistry. There was
no significant difference in the average amounts of NM23 mRNA between cell lines derived from metastatic
and primary melanomas. The level of NM23 mRNA was also determined for three pairs of poorly metastatic
parental (P) and their highly metastatic variant (M) cell lines; the ratios for M/P were 1.2, 0.98 and 0.80. Next
we used immunocytochemistry to study NM23 protein in normal skin, benign naevi and primary and
metastatic melanomas. Melanocytes in all normal skin and benign samples were positive for NM23; however
most primary melanomas (7/11) were not stained by the antibody. All metastatic melanoma samples (5/5) were
positively stained. Findings were similar with an antiserum reactive with both forms of NM23 (H1 and H2),
and with an antibody specific for NM23-H1. No relationship was apparent between NM23 immunoreactivity
in primary tumours and their aggressiveness or prognosis. Hence, in contrast to the situation described for
murine melanoma, the amount of NM23 mRNA or protein in human melanoma did not correlate inversely
with metastasis.
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Successful metastasis is a complex series of biological events
(MacDonald and Steeg, 1993; Dorudi and Hart, 1993).
Acquisition ofmetastatic capacity by a cell appears to involve
both positive and negative changes in gene expression (Liotta
et al., 1991). Hence subtractive and differential cDNA
hybridisation methods provide approaches for the isolation
of relevant genes (Hart and Easty, 1991), starting from
closely related tumour cell lines selected for differing
metastatic behaviour in experimental assays (Fidler and
Radinsky, 1990). Thus a panel of subclones from mouse
melanoma K1735 was used to isolate the metastasis-
suppressor gene nm23 on the basis of a lower level of
expression in highly metastatic compared with poorly
metastatic clones (Steeg et al., 1988). The human homo-
logues of the gene are NM23-H1 and NM23-H2, both
mapping to chromosome 17q21 (Chang et al., 1994). They
encode the monomers of nucleoside diphosphate kinases
(NDPK)-A and -B respectively. Both are homohexamers,
except that hybrid forms containing both NDPK-A and -B
subunits have been found in erythrocytes (Gilles et al., 1991).
It is not known whether these mixed forms occur elsewhere.
These proteins may also have other functions, notably a
DNA-binding activity (Postel et al., 1993) or a protein serine
kinase activity (MacDonald et al., 1993; Bertheau et al.,
1994). Suppressor activity was further indicated when
transfection of murine nm23 into the highly metastatic
melanoma subline K1735 TK resulted in significantly
reduced metastasis (Leone et al., 1991).
More recent studies however have not shown a universal
pattern of deficient expression of this gene in metastatic
tumours. In other mouse melanoma sublines (Parker and
Sherbet, 1992), further clones derived from line K1735, and
human tumour cell clones (Radinsky et al., 1992), no
correlation was detected between nm23 transcription levels
and metastatic potential. In studies of various human
cancers, an inverse correlation of NM23 mRNA or protein
expression with metastatic potential has been described in
some cases (Bevilacqua et al., 1989; Hennessy et al., 1991;
Hirayama et al., 1991; Fl0renes et al., 1992), but not others
(Sastre-Garau et al., 1992; Radinsky et al., 1992; Higashiya-
ma et al., 1992; Sawan et al., 1994). Moreover, groups who
also examined related normal or benign tissues generally
reported that expression of NM23 was lower there than
typically seen in malignant lesions (e.g. Lacombe et al., 1991;
Hirayama et al., 1991; Hailat et al., 1991; Sawan et al., 1994).
The amount of NM23-Hl mRNA in human metastatic
melanoma has been studied by two groups (Fl0renes et al.,
1992; Xerri et al., 1994). Both groups reported generally
decreased amounts in more aggressive tumours. Fl0renes and
colleagues found that metastases appearing soon after
diagnosis of the primary tumour had significantly lower
levels of NM23 mRNA than metastases that developed after
a longer time. Similarly Xerri et al. (1994) when studying
patients with melanoma metastasis confined to regional
lymph nodes, found significantly longer survival associated
with higher levels of NM23 mRNA in the resected nodes.
Conversely Fl0renes et al. (1992), also found lower levels of
NM23 mRNA in benign naevi than in metastases, and
speculated that NM23-H1 might act as a suppressor of
differentiation in melanocytes, as previously suggested for
NM23-H2 in lymphocytes (Okabe-Kado et al., 1992).
Data from Northern blotting using fresh tumour samples
will be influenced by any non-neoplastic cells present
(including stromal cells and any inflammatory infiltrate),
and also will not provide information regarding tumour
heterogeneity. To circumvent these problems we have used:
(1) Northern blotting to study 30 cell lines derived from
lesions at various stages of melanoma progression; and (2)
immunocytochemistry to study human biopsy material. To
ensure that data from cell lines were relevant to metastasis we
included three pairs of poorly metastatic parental lines and
their highly metastatic variant lines. These human cell lines
were previously selected and assayed in nude (thymus-
deficient) mice (Ormerod et al., 1986, Herlyn et al., 1990),
and so resemble the murine melanoma cell lines used initially
to isolate nm23 (Steeg et al., 1988).
The amount of NM23 mRNA (by Northern blotting) has
been shown to correlate well with protein expression assessed
with an anti-NM23 polyclonal antiserum (Sawan et al., 1994).
We have used the same antiserum in an immunohistochem-
ical study of the expression of NM23 in pigmented lesions at
various stages of tumour progression.
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Materials and methods
Patients and Tumours
Five biopsies of normal skin and biopsies of five benign
compound naevi, five dysplastic melanocytic lesions, five
melanomas in situ, five radial growth phase (RGP)
melanomas, six vertical growth phase (VGP) melanomas
(Clark et al., 1989) and five metastatic melanomas were
obtained from the archives of the Department of Histo-
pathology, St. George's Hospital. Clinical follow-up was
available in every case. Tissue had been fixed in 10% neutral
buffered formalin, routinely processed and embedded in
paraffin wax. Sections (5 rim) were cut and floated on to
poly-L-lysine coated glass slides for immunohistochemistry.
Before inclusion in the study, haematoxylin and eosin stained
sections were reviewed by the dermatopathologist (MEF) to
verify the pathological diagnosis.
Immunohistochemistry
An alkaline phosphatase-conjugated second antibody was
used for immunostaining (Warburton et al., 1982). This
method produces a red product that is easily distinguished
from melanin pigment. Mounted sections were dewaxed,
taken to water and preincubated in 5% goat serum in PBSA
(Dulbecco's phosphate-buffered saline lacking calcium and
magnesium chlorides), to block non-specific binding. They
were next incubated with anti-NM23 antiserum (Sastre-
Garau et al., 1992) that had been affinity purified using
recombinant NDPK-A (Sawan et al., 1994). This antiserum
has a preference for NDPK-A but also cross-reacts with
NDPK-B (Sawan et al., 1994). The serum was diluted 1:500
in PBSA with 5% normal human serum. Incubation was
overnight at 4°C. Sections were washed in PBSA and
incubated with alkaline phosphatase-conjugated goat anti-
mouse antiserum (Sigma) diluted 1:60, for 1 h at room
temperature. They were then washed in PBSA and the
antibody visualised by developing in substrate buffer:
naphthol AS-B1 phosphate (sodium salt) and fast red (TR
salt) in veronal acetate buffer, pH 9.2, containing levamisole
to inhibit endogenous alkaline phosphatase activity as
previously described (Warburton et al., 1982). Sections were
counterstained with haematoxylin. For negative controls the
primary antibody was replaced by normal rabbit serum.
Representative sections (more than halfofthe total stained
previously with the rabbit antibody and additional new
blocks) were also stained with a monoclonal antibody to
NM23-H1 that does not cross-react with NM23-H2 (nm23-
H1/NM301, Santa Cruz Biotechnology). This was diluted
1:50; detection was with an alkaline phosphatase-conjugated
rabbit anti-mouse antiserum (Sigma). Antibody incubation
and substrate development were as described above.
Standardisation of immunostaining was made possible by
inclusion of normal skin in each experiment. Normal skin
consistently contained intensely stained sweat and sebaceous
glands and weakly stained or unstained epidermis. Normal
skin present at the edges of some test sections gave a further
control. Sections were graded using a five point scale as
previously described (Sawan et al., 1994). Absence of staining
(0) and weak, equivocal staining (+/-) were classed as
negative, while unequivocal weak (+), moderate (+ +) and
intense (+ + +) staining were classed as positive.
Culture of melanocytes and melanomas
Normal melanocytes and melanomas were cultured as
previously described (Easty et al., 1993). Biological details
of most of the lines used here are tabulated in Easty et al.,
(1995a,b). Melanoma cell line RPMI-7932 and all COLO
lines were gifts from Professor G. Moore (Department of
Health, Denver, CO, USA) (Morse and Moore, 1993). Lines
MM96, MM485, ME1402 and ME10538 were gifts from Dr
P Parsons (Queensland Institute of Medical Research,
Brisbane, Australia). 451LU and all WM lines were gifts
from Professor M Herlyn. Cell line 451LU is a highly
metastatic variant cell line derived from the parental cell line
WM164 which has only a very low rate of spontaneous
metastasis (Herlyn et al., 1990). DX3 and SKMEL23 cells
were donated by Dr T Albino (Memorial Sloan-Kettering
Cancer Center, New York, USA). DX3LT5.1 is a highly
metastatic variant cell line that was derived from the poorly
metastatic parental line DX3 following brief exposure to 5-
azacytidine and repeated passage through the lungs of nude
mice by the intravenous route (Ormerod et al., 1986).
Similarly A375M is a highly metastatic variant line that
was derived from the poorly metastatic parental line A375P
in the same way. Thus, three pairs of poorly metastatic
parental lines and their highly metastatic variants were
examined for NM23 expression. The metastatic behaviour
of these variants is stable (Ormerod et al., 1986; Herlyn et al.,
1990); nevertheless the earliest available passage was used for
Northern blotting to minimise clonal drift. All melanoma
lines were cultured in Dulbecco's modification of Eagle's
medium with 5% fetal calf serum, except for WM1650, a line
derived from the radial growth phase of a primary
melanoma, which was grown in melanocyte medium (Easty
et al., 1993).
Northern blotting analysis
Total RNA was isolated and poly (A)' RNA selected by
oligo(dT)-cellulose chromatography as described previously
(Easty et al., 1993). Aliquots (10 pg) of poly(A)-enriched
RNA were separated by electrophoresis in agarose gels
containing formaldehyde and transferred to nitrocellulose
membranes. Prehybridisation (4 h) and hybridisation (18 h)
were at 42°C in 5 x SSPE, 5 x Denhardt's solution, 50% w/v
formamide, 500 pg ml-' salmon sperm DNA and 10% w/v
sodium dodecyl sulphate (SDS). The final wash was in
0.5 x SSPE and 0.1% SDS at 65°C. After washing, filters
were autoradiographed for up to 1 h. The probe used was an
NM23-HJ sequence, a gift from Dr P Steeg (Steeg et al.,
1988). This would be expected to detect NM23-H2 as well,
because of the high homology of the two coding sequences.
Probes were labelled by random hexamer priming (Feinberg
and Vogelstein, 1984) to a specific activity of about
2 x 109 d.p.m. ug-' DNA. For normalisation of RNA
loading, blots were rehybridised with a probe for house-
keeping gene glyceraldehyde phosphate dehydrogenase
(GAPDH), a gift from Professor M Clemens, St. George's
Hospital Medical School. Quantitation of autoradiographs
was by laser densitometry, using Image Quant software
(Molecular Dynamics, Sunnyvale, CA, USA). The relative
level of expression was calculated as the ratio of signal in the
area of the NM23 band to that for GAPDH mRNA in the
same cell line. Figures were then normalised to the level in
one cell line (DX3LT5.1), defined as 100 as described (Easty
et al., 1993).
Results
Northern blotting
By Northern analysis a 0.8 kb NM23 transcript was detected
in all cell lines studied. This mRNA was highly expressed
(easily detected by autoradiography in 30 min), although with
an 11-fold range of level (Figure 1). The levels of NM23
mRNA in cell lines derived from primary and metastatic
melanomas were compared (Figure 2 and Table I). Median
mRNA indices were 73.5, 55 and 85 in normal melanocytes,
primary and metastatic melanomas respectively. Levels
ranged widely in the tumour cells and there was an apparent
trend towards higher mRNA levels in metastatic than in
primary melanoma lines (Table I), although this was not
statistically significant. Cell lines WM239A and WM115 were
from the same patient, derived from a metastasis and a
primary melanoma respectively; WM239A had a 5-fold
higher level of NM23 mRNA than WM115.NM23 and melanoma metastasis
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Three pairs of poorly metastatic cell lines (P) and highly
metastatic variants (M) were examined by Northern blotting
(Table I). The ratios M/P for NM23 mRNA were: 1.20
(DX3LT5.1/DX3), 0.98 (A375M/A375P), and 0.80 (451LU/
WM164). Thus there was no obvious relationship between
the level of NM23 transcription in these cell lines and their
metastatic behaviour in nude mice. Nor could we detect any
strong relationship with cell differentiation. The normal
melanocytes and two of the melanoma lines used, WM1650
and SKMEL23, were morphologically differentiated, pigmen-
ted and non-tumorigenic in nude mice; however there was an
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8-fold difference between the NM23 mRNA indices for these
two melanoma lines and the values for melanocytes were
intermediate (Table I).
Immunohistochemistry
Initially, a rabbit anti-NM23 polyclonal antibody was used
for immunohistochemistry. In normal skin this antiserum
bound strongly (+ + +) to some epidermal adnexal
components such as sweat gland coils and sebaceous
glands, whereas the epidermis was unstained or only weakly
co
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Figure 1 Northern blot analysis of poly(A)-enriched RNA from
cultured melanocytes and cell lines from primary melanomas
(WM115, MM485) and melanoma metastases (all other lines):
10ig was loaded per lane. Filters were hybridised to probes for
NM23-HJ and GAPDH and autoradiographic signals were
quantitated by laser densitometry. To control for loading the
ratio of signal for NM23 to that for GAPDH was calculated for
each cell line and then normalised to the ratio for one cell line
(LT5.1). Both primary and metastatic lines show a range of levels
of NM23 mRNA; see Table I for details.
Figure 2 Northern blot analysis of poly(A)-enriched RNA from
poorly metastatic parental melanoma cell lines (WM164, DX3,
A375P), and their closely related highly metastatic variant
sublines (451LU, LT5.1, A375M): 10jug was loaded per lane.
Probes were for NM23-HJ and GAPDH. Quantitation of
autoradiographs was by laser densitometry; see Table I for
details.
Table I Quantitated mRNA levels in melanocytes and melanoma cell lines
Normal melanocytes
mRNA index
Primary melanoma lines Metastatic melanoma lines
Line mRNA index Line mRNA index
65 WMI15 23 451LU
ME10538 37 SKMEL23
WM98-1 50 WM852
MM485 60 WM164
ME1402 67 C32TG
WM1158
COLO 679
COLO 792
84 WM1650 188 DX3
COLO 818
COLO 858
DX3LT5.1
COLO 849*
COLO 800
COLO 857*
COLO 832*
COLO 749
GRM
COLO 839*
WM239A
COLO 829*
COLO 845*
A375M
A375P
22
22
27
28
36
40
66
68
79
85
98.5
100
107
108
115
116
121
125
125
126
146
157
189
193
mRNA levels were quantitated by Northern blotting and laser densitometry of
autoradiographs (Materials andmethods). Levels are relative to GAPDHmRNA levels in
each line and the index is obtained by dividing by the value for one line (DX3LT5.1) and
multiplying by 100 (Easty et al., 1993). *These lines were obtained from different
metastatic sites in the same patient. Thus they were notindependent and were represented
by a single median value (121) for statistical purposes. The dashed line represents the
median value for normal melanocytes. The difference between primary and metastatic
lines was not significant by the x2 test on the numbers ofvalues falling above and below
this line (P<0.1), not by Mann-Whitney rank test.
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stained (+) (Figure 3). This provided an internal control for
NM23 reaction in pathological material that contained
adjacent normal skin. Inflammatory and stromal cells in
lesions (including lymphocytes, macrophages and fibroblasts)
were generally unstained.
Most pathological specimens showed heterogeneous
staining of cells forming the lesion. Staining was generally
cytoplasmic. There was intense staining of melanocytes in
junctional nests of compound naevi (+ + +) with some more
weakly stained cells (+ to + +) in the dermis (Figure 3);
there was some indication of reduced staining with increasing
depth in the dermis (from + + + to + +). Similar patterns
were observed in compound naevi with melanocytic dysplasia
(not shown). In contrast, primary melanomas (both RGP and
VGP) were more weakly stained, areas within a lesion
varying from 0 to + or occasionally + +. Lesions were
scored as positive if they contained any clearly stained
malignant cells. Some primary melanomas (7/11) were
unstained (0) or gave at best an equivocal reaction (+/-),
and so were classed as negative (Figure 4). Melanoma
metastases also tended to react heterogeneously for NM23.
However, in all samples from metastases the majority of
melanoma cells were moderately or highly stained and lesions
were thus scored as + + or + + + (Figure 5). Nuclear
staining was observed in some cases.
Similar patterns of staining were obtained when the anti-
NM23-H1 monoclonal antibody was used, except that in
some compound naevi immunostaining was only moderate
(+ to + +), and occasionally restricted to one part of the
naevus in contrast with the situation with the rabbit anti-
NM23 antibody which bound to all parts. The reaction in
melanoma metastases was intense (+ + +) and the pattern of
staining closely resembled that found previously with the
rabbit antiserum.
There was no apparent relationship between NM23
immunoreactivity and prognosis. Positive NM23 staining
was seen in 3/6 primary melanomas from which metastasis
was subsequently detected (median time from resection of the
primary tumour, 7 months, range 1-24 months), and in 1/5
Figure 4 Lack of immunohistochemical staining for NM23 in a
VGP primary melanoma using a rabbit polyclonal antibody.
There was no clear staining in tumour cells. Brown melanin can
be seen in the cytoplasm of some melanoma cells.
Figure 3 Immunohistochemical staining for NM23 in compound
naevi using (a) a rabbit polyclonal antibody, and (b) a mouse
monoclonal antibody. There is an intense reaction in naevus cells
(solid arrow), whereas staining in the epidermis (open arrow) is
weak to negative. Individual positive cells in the basal epidermis
near the naevus are likely to be naevus cells.
Figure 5 Immunohistochemical staining for NM23 in a
melanoma metastasis to a lymph node. (a) Rabbit polyclonal
antibody and haematoxylin counterstain. (b) Mouse monoclonal
antibody. There is intense staining of trabeculae of tumour cells
(solid arrow). Stromal cells and lymphocytes are negative (open
arrow).NM23 and melanoma metastasis
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Table H Immunohistochemical staining for NM23 in melanocytic lesionsa
Lesion Percentage oflesions expressing NM23 Comments
Compound naevi 100 (5/5) Generally heterogeneous labelling of cells:
junctional nests, + + +; cells in dermis, + to + +
Atypical naevi 100 (5/5) As for compound naevi
Primary melanomasb 36 (4/11) Heterogeneous labelling (4/4): - to + or to + +
Metastatic melanomas 100 (5/5) Heterogeneous labelling in all lesions, - to + + or
to +++
aImmunohistochemical staining with a rabbit polyclonal anti-NM23 antibody. bPrimary melanomas
positive for NM23 were 3 VGP and 1 RGP. After resection and follow-up, one ofthese patients had no
evidence ofsecondary disease and three patients developed metatases; times from excision ofprimary to
first metastasis were 6, 8 and 14 months. Primary melanomas negative for NM23 were 3 VGP and 4
RGP; three such patients had no evidence of secondary disease whereas four patients developed
metastases after 1, 2, 18 and 24 months.
tumours from which it was not detected (median follow-up
48 months, range 13-58 months). Moreover, both RGP and
VGP primary melanomas had similar patterns of staining
with the anti-NM23 antiserum, although they have different
prognoses: RGP tumours are rarely metastatic whereas VGP
tumours are frequently metastatic.
Discussion
Some previous studies have concluded that the expression of
NM23 in certain human cancers correlates inversely with the
incidence of metastases (Hennessy et al., 1989; Hirayama et
al., 1991; Fl0renes et al., 1992; MacDonald and Steeg, 1993).
The approach has been often to determine the level of NM23
expression in primary tumours in comparison with the
incidence of metastasis (or prognosis) in the patients.
Alternatively, Fl0renes et al. (1992) and Xerri et al. (1994)
determined the level of NM23 mRNA in melanoma
metastases and compared this with the aggressiveness of the
primary tumour. Here we examined primary melanomas and
related the expression of NM23 to the same measure of
tumour aggressiveness (the interval between diagnosis of
primary and secondary tumours) as used in the earlier study
(Fl0renes et al., 1992).
The NM23-HI and -H2 transcripts are 88% homologous,
and Northern analyses that use full-length NM23 probes will
detect mRNA for both genes (Leone et al., 1993). Such
studies include the present work and two previous reports on
NM23 in human melanoma (Fl0renes et al., 1992; Xerri et
al., 1994). These genes are not always similarly regulated and
the Hl gene product may be a better marker for metastasis in
at least some tumours (Tokunaga et al., 1993). Nevertheless,
both previous studies of human melanoma found reduced
amounts of total NM23 mRNA in more aggressive tumours.
For the present study we used a similar probe, and a rabbit
polyclonal antibody that cross-reacts with both gene
products. For comparison we also included an antibody
specific for NM23-H1.
We did observe generally decreased NM23 protein levels
in primary melanomas as compared with melanocytes in
naevi. More than half the primary melanomas were unstained
(Table II). However, no relationship was apparent between
the amount of NM23 in the primary melanomas and the
subsequent incidence of metastasis for this small group of
patients. Immunostaining for NM23 in these lesions was
generally heterogeneous. Tumour heterogeneity for metastatic
propensity has been well documented (e.g. Fidler and
Radinsky, 1990), and it is possible that metastases arose
selectively from cells lacking NM23 within these lesions even
when the lesion overall was classified as positive. However, if
so, one might expect that melanoma metastases would have
at least as low a level of NM23 expression as primary
tumours, and that primary tumours expressing no NM23
would have the poorest prognosis. Neither was the case: we
found high levels of NM23 protein in all metastatic
melanomas studied.
With the polyclonal antibody there was intense immuno-
histochemical staining for NM23 in benign naevi. This
apparently contrasts with the finding of low NM23-HI
mRNA levels in naevi by Florenes et al. (1992). Naevi are
generally small, thin, discontinuous lesions and biopsies are
likely to contain epidermis and dermis, which express little
NM23 and might dilute NM23 mRNA from naevus cells.
Another possible source of discrepancy might be high
expression of NM23-H2/NDPK-B in naevi. This might be
detected to a lesser extent by the NM23-HI gene probe than
by the rabbit antibody. Consistent with this, the NM23-Hl-
specific antibody reacted only weakly with some naevi.
However, other naevi were strongly stained, indicating high
expression of NM23-HI protein in at least some naevi.
Moreover, from results with this antibody, NM23-HI was
highly expressed in all melanoma metastases tested.
NM23 mRNA levels in cultured melanoma cells ranged
from lower than those in cultured normal melanocytes to
several fold higher; there was no significant difference
between the distributions of amounts in metastatic and
primary melanoma cell lines. Using immunohistochemistry
we found more NM23 protein in metastases than in primary
melanomas. This tendency seems surprising given that it was
in melanoma that a metastasis-suppressor activity of nm23
was first demonstrated. Recalling the often high expression of
NM23-HJ mRNA in metastatic cell lines, it is possible that
an abnormal form of NM23-HI is being overexpressed. It
was recently reported that point mutations of NM23-HI can
be coupled with amplification of the gene in neuroblastoma
(Chang et al., 1994). This is reminiscent of findings with the
p53 tumour-suppressor gene: either (1) inactivation and
silencing of the normal p53 gene; or (2) overexpression of a
mutated form of the gene can be oncogenic (Levine, 1993).
We are currently examining this further by sequencing
NM23-HJ genes from metastatic melanomas. Our results
raise the possibility that, while in primary human melanoma
expression of the NM23-HJ gene tends to be repressed,
overexpression of an altered gene becomes a more common
mechanism during progression and metastasis.
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